Back to Journals » International Journal of General Medicine » Volume 6

Action of irbesartan on blood pressure and glucose/lipid metabolism, in hemodialysis patients with hypertension

Authors Onishi A, Morishita Y, Watanabe M, Numata A, Tezuka M, Okuda K, Tsunematsu S, Sugaya Y, Hashimoto S, Kusano E

Received 9 February 2013

Accepted for publication 8 May 2013

Published 28 May 2013 Volume 2013:6 Pages 405—411

DOI https://doi.org/10.2147/IJGM.S43850

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Akira Onishi,1 Yoshiyuki Morishita,1 Minami Watanabe,1 Akihiko Numata,1 Mikio Tezuka,2 Kosuke Okuda,3 Sadao Tsunematsu,4 Yasuhiro Sugaya,5 Shinichi Hashimoto,5 Eiji Kusano1

1
Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan; 2Kurosu Hospital, Tochigi, Japan; 3Okuda Clinic, Tochigi, Japan; 4Yuki Clinic, Ibaraki, Japan; 5Ninomiya Central Clinic, Tochigi, Japan

Background: Irbesartan has been reported to have beneficial effects on glucose/lipid metabolism in addition to an antihypertensive effect; however, such effects have not been clarified in hemodialysis (HD) patients. We investigated the effects of irbesartan on blood pressure (BP) as well as glucose/lipid metabolism, in HD patients with hypertension.
Methods: Seventeen HD patients with hypertension, aged 62.7 ± 12.5 years, were treated with daily oral administration of 50 to 100 mg of irbesartan for 12 weeks. Then, the changes of BP as well as glucose metabolism (random serum glucose level and serum glycosylated hemoglobin [HbA1c] level) and lipid metabolism (serum low-density lipoprotein cholesterol [LDL-chol] level, serum high-density lipoprotein cholesterol [HDL-chol] level, and serum triglyceride [TG] level) were evaluated.
Results: Irbesartan significantly reduced systolic BP (154.9 ± 12.8 to 139.4 ± 13.1 mmHg (P < 0.01) and diastolic BP (78.9 ± 9.1 to 72.2 ± 9.7 mmHg, P < 0.01). It also reduced LDL-chol (77.6 ± 19.1 to 72.0 ± 18.6 mg/dL, P < 0.05), whereas it did not significantly affect random serum glucose (129.3 ± 46.9 mg/dL to 130.6 ± 47.2 mg/dL), HbA1c (5.58% ± 1.41% to 5.49% ± 1.11%), TG (104.3 ± 65.8 mg/dL to 100.2 ± 59.9 mg/dL), or HDL-chol (44.8 ± 17.1 mg/dL to 45.7 ± 15.6 mg/dL).
Conclusion: Irbesartan is effective for BP control and may have beneficial effects on lipid metabolism in HD patients.

Keywords: irbesartan, hemodialysis patients, blood pressure, glucose/lipid metabolism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]